Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 7.1% in the afternoon session after the company trimmed the upper ...

Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2025 results exceeding the market’s revenue expectations, but sales ...

We may be a step closer to a highly effective mRNA vaccine against HIV, but tests so far reveal that the approach can cause ...

For the quarter ended June 2025, Moderna (MRNA) reported revenue of $142 million, down 41.1% over the same period last year. EPS came in at -$2.13, compared to -$3.33 in the year-ago quarter. The ...

HIV vaccine efforts have been slowed by the difficulty of getting neutralizing antibodies to target the correct locations of ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Heart attacks remain a leading cause of death and disability worldwide. The permanent loss of heart muscle cells—known as ...

The results suggest the possibility of a vaccine for HIV/AIDS, which killed more than half a million people last year.

A breakthrough in our understanding of mRNA delivery systems in the body may allow for more direct treatments for ...

Researchers found that the stereochemistry of lipids like ALC-315 affects mRNA drug safety and efficacy, offering a path to ...

Scientists used a mRNA-based vaccine to reliably trigger antibodies that block HIV infection in people and monkeys ...